AV-101 Phase 2 Monotherapy Study for MDD
AV-101 is currently being evaluated in an ongoing Phase 2 monotherapy study for the treatment of MDD, a study being conducted and funded by the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Dr. Carlos Zarate of the NIMH is the Principal Investigator of the study. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics, with potential to further drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. VistaGen's development strategy for AV-101 is focused on establishing it as the primary augmentation option for individuals with MDD with inadequate response to standard antidepressants, displacing adjunctive use of atypical antipsychotics such as aripiprazole in the current depression treatment paradigm. VistaGen currently anticipates topline results of this NIMH-sponsored Phase 2 study in the first half of 2018.
Study Center and Contact
|National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892
|Carlos A Zarate, M.D.|
For more information about the study, please visit www.clinicaltrials.gov.